Abstract: According to one aspect of the present disclosure, provided is a film for hair dyeing comprising: a base film; and an ink layer for hair dyeing on the base film, wherein the ink layer for hair dyeing comprises a first pigment for masking hair color, a second pigment for expressing desired color on hair, a resin, and wax. According to one aspect of the present disclosure, provided is a printer for hair dyeing comprising: a body including a printer head; and a film cartridge for hair dyeing mounted to the body over the printer head; wherein the printer head may be in contact with a film included in the film cartridge for hair dyeing and comprises a hair holder of which one end is connected to one end of the body so as to be folded and unfolded with respect to the body. The hair may be grabbed between the body and the hair holder, and the printer head may be positioned on a side facing the hair holder.

Abstract: Personal care compositions contain a carrier that includes at least one hydrophobic component or gelling agent and optionally water, coral-shaped metal (e.g., gold) nanoparticles dispersed throughout the carrier and forming a nanoparticle stabilizing matrix within the carrier, and spherical-shaped metal (e.g., silver) nanoparticles dispersed throughout the carrier and stabilized by the nanoparticle stabilizing matrix formed by the coral-shaped metal nanoparticles. The spherical-shaped metal nanoparticles act as a preservative and prevent spoiling of personal care products. The coral-shaped metal nanoparticles provide personal care products with hydrodynamic and antioxidant properties. The weight ratio of coral-shaped metal nanoparticles to spherical-shaped metal nanoparticles can be 1:1 to 50:1. The concentration of coral-shaped metal nanoparticles can be 1 ppm or greater, and the concentration of spherical-shaped metal nanoparticles can be less than 1 ppm.

Abstract: This disclosure provides CaCO3 and/or ZnO-loaded microcapsules for use as whitening agents in foods, beverages, supplements, pharmaceutic products, cosmetic products, and personal care products.

Abstract: A transparent antibacterial composition comprises water, alcohol, a humectant, and a sensory oil. A method of making a transparent antibacterial composition comprises combining a sensory oil and a humectant forming a first phase; combining water with an alcohol forming a second phase; combining the first phase and the second phase forming a third phase; and adding a neutralizer to the third phase, thereby forming the antibacterial composition.

Abstract: In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16%by weight; caprylyl glycol 0.45-3%by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1%by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13%by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that has a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

Abstract: The present invention relates to the use of 1,3-propanediol as an agent to balance the growth of commensal skin microorganisms of dry and sebaceous skin and thus to foster the maintenance of a healthy skin barrier.

Abstract: An antibacterial composition comprises water, alcohol, a moisturizing oil, wherein at least 50% of droplets of the moisturizing oil present in the antibacterial composition have a particle size of 5 to 25 micrometers, preferably 6 to 15 micrometers; and optionally a sensory oil. A method of making an antibacterial composition comprises dispersing a thickening agent in water forming a first phase; combining a moisturizing oil, a sensory oil, and a humectant forming a second phase; combining the first phase with an alcohol forming a third phase; adding the second phase to the third phase, forming a forth phase; and adding a neutralizer to the fourth phase, thereby forming the antibacterial composition.

Abstract: The present invention is directed to a hair treatment composition and method for its use. Embodiments of the hair treatment composition include at least organic acid components comprising an organic dicarboxylic acid and an organic fatty acid, a fatty hydrocarbon and a fatty acid ester. The hair treatment composition can serve as a hair conditioner, a leave-on composition or a shampoo depending upon additional appropriate additives.

Abstract: A polymer/hydrophobic ester oil blend is provided comprising (a) a cosmetically acceptable hydrophobic ester oil; and (b) a thickening polymer powder, thickening polymer, wherein the thickening polymer is a silylated cellulose polymer, comprising a cellulose polymer functionalized with —Si(R1)3 groups; wherein each R1 is independently selected from the group consisting of a hydrogen, a C1-8 alkyl group, a C1-8 haloalkyl group, an aryl group, a C1-8 alkylaryl group and a C1-8 haloalkylaryl group; and wherein the cellulose polymer has a weight average molecular weight of 50,000 to 1,500,000 Daltons. Also provided are suncare formulations containing same and methods of using same.

Abstract: The invention provides the use of a hair care composition comprising piroctone olamine, a zinc salt and a silicone for preventing or reducing shedding of hair club fibres from hair follicles, and/or preventing or reducing hair breakage, thereby preventing or reducing hair fall.

Abstract: Disclosed are compositions, particularly topical compositions comprising a urolithin, cosmetic compositions comprising a urolithin and cosmetic compositions comprising a urolithin and trehalose, compositions comprising urolithin and niacinamide (nicotinamide) and compositions comprising urolithin, trehalose, niacinamide and caffeine. Furthermore, the invention relates to urolithin for use in improving skin barrier function, for example, maintaining skin hydration, improving skin elasticity and firmness, and/or increasing or maintaining skin layer thickness.

Abstract: The disclosure relates to compositions comprising gluconolactone and at least one nonionic film forming polymer. The compositions can be used for styling or shaping hair, and/or for providing manageability benefits to hair, in particular curly hair. The disclosure also relates to methods of using the compositions.

Abstract: The disclosure relates to compositions comprising gluconolactone and at least one compound chosen from amino acids, amino sulfonic acids, and salts thereof. The compositions can be used for lengthening the visual appearance of hair, in particular curly hair. The disclosure also relates to methods of using the compositions.

Abstract: Preparations and methods disclosed herein may be used for transdermal delivery of a peptide comprising a sequence of L-K-E-K-K (SEQ ID NO: 1) to the scalp for hair growth stimulation. In some embodiments, preparations and methods disclosed herein may be used for transdermal delivery of the peptide comprising SEQ ID NO: 1 along with bacterially and/or microbially active ingredients.

Abstract: The current application discloses a composition that comprises at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines for the treatment and cosmetics of animal hair, in preference human hair. There are several hair styling methods that involve breakage and reestablishment of disulfide bonds, allowing relaxation and straightening of the hair. However, the most effective methods currently used to modulate hair contain harmful chemicals. Thus, there is a constant demand for formulations that efficiently model the hair fiber without damage. Thus, the present invention aims to provide a composition for treatment of the hair, including animal and human hair, without the use of chemicals harmful to the hair fiber and consumer health and uses of said compositions in shampoo, lotion, serum, cream, conditioner, foam, elixir, oil, aerosol or mask.

Abstract: The invention relates to aqueous formulations for topical nail application. The invention also relates to compositions for use in the treatment of a fungal nail infection, the composition being applied over a defined period.

Abstract: A water based composition contains a sugar based delivery system, coemulsifiers, a positively charged molecule, oil, optional auxiliary materials, and optional lipophilic active ingredients. The composition is encapsulated to be used in personal care products including cosmetics. The composition is penetrating into the skin and is, depending on the active included, able to stabilize the substance and reduce its irritation potential.

Abstract: Provided are cellulose acetate particles. The cellulose acetate particles have an average particle size of 80 nm or greater and 100 ?m or less, a sphericity of 0.7 or greater and 1.0 or less, and a relative specific surface area of 3.0 or greater and 20 or less. A total degree of acetyl substitution of the cellulose acetate is 0.7 or greater and 3.0 or less.

Abstract: An emulsifier composition includes microcrystalline cellulose; at least one biogum of microbial origin; and, optionally, at least one cellulose ether or derivative thereof. Emulsions and personal care formulations including the emulsifier composition, methods of preparing the emulsifier composition, and a method of using the emulsifier composition to stabilize an emulsion which includes an oil phase and a water phase are also described.

Abstract: The present invention relates to a cosmetic active substance obtained from a duckweed of the species Spirodela polyrhiza and its cosmetic uses, in particular its use as a plumping agent.

Abstract: A method for manufacturing a plant fermented product using a plant fermented broth, includes: mixing 5 to 30 parts by weight of a first plant material, 100 parts by weight of water, 1 to 10 parts by weight of sugar, and 0.05 to 1 part by weight of lactic acid bacteria, and fermenting the resulting mixture at room temperature in a range of 5 to 25° C. for 30 days to 6 months so that the material becomes acidic at pH 4 or less to obtain a first fermented broth; mixing 5 to 30 parts by weight of a second plant material, which is the same as or different from the first plant material, 100 parts by weight of water, 1 to 10 parts by weight of sugar, and 1 to 10 parts by weight of the first fermented broth, and fermenting the resulting mixture d product.

Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 µg/kg about 200 µg/kg (such as about 10 µg/kg to about 45 µg/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

Abstract: A pharmaceutical composition for ophthalmic dosing or administration is disclosed, comprising (i) a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient. The pharmaceutical composition is formulated as a suspension. The composition may be used to treat ophthalmic disorders and diseases caused by abnormal proliferation of angiogenesis.

Abstract: Described herein are compositions and methods of use thereof. The compositions include a first population of inhalable particles and a second population of inhalable particles, wherein the first inhalable particles include a first mucolytic contained within a first biodegradable encapsulation, and the second population of inhalable particles includes the first or a second mucolytic contained within a second biodegradable encapsulation.

Abstract: Hydrogels and preparation of biocompatible, in situ gelling and injectable hydrogels composed of cellulose nanofibrils and using them for tissue and organ repair and regeneration. The present invention demonstrates cellulose nanofibrils with tuned size (fibril length and distribution), high crystallinity, and high purity, variable concentration in water, and controlled charge for injectable hydrogels. The current application discovers that in situ gelling can be achieved by controlling the degree of substitution of cellulose nanofibrils through carboxymethylation. After injection, they can form three-dimensional gels and provide attachment sites and guidance for cells to facilitate tissue and organ repair. They can be also loaded with drugs, growth factors, or signaling molecules to be delivered to targeted locations in the body and released in a controlled manner.

Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Abstract: A contact lens product having an antioxidative function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one non-enzymatic antioxidant. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.5 nm to 40 nm. The at least one non-enzymatic antioxidant is present in an amount greater than 0 wt% and less than 20 wt% based on the composition being 100 wt%.

Abstract: The present invention addresses the problem of providing a pregnancy-induced hypertension syndrome therapy composition having controlled placental permeability. Provided are nicotinamide-encapsulating micelles having a particle diameter of 25-100 nm. Controlling the particle diameter of the nicotinamide-encapsulating micelles enables control of placental permeability so as to make it possible to accumulate nicotinamide-encapsulating micelles in a placental while suppressing transfer to a fetus. Administering the nicotinamide-encapsulating micelles brings about a superior effect of reducing blood pressure during a pregnancy-induced hypertension syndrome.

Abstract: Provided is a dispersion composition containing: a dispersion medium; and particles containing a target substance. The dispersion composition includes at least one type of surfactant having a critical micelle concentration or more and does not contains a solubilizer, and the target substance is cyclosporin A. Products such as pharmaceuticals, foods, beverages, and cosmetics, containing the dispersion composition are also disclosed.

Abstract: A composition for delivering a drug includes a drug carrying liposome carrying a drug in a liposome, and an empty liposome which does not carry the drug and includes phospholipid having a head and two fatty acid chains, wherein both of the two fatty acid chains comprises omega-3 fatty acids or their derivatives.

Abstract: This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

Abstract: This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

Abstract: The present invention relates to a lyophilized pharmaceutical composition for reconstitution in an aqueous carrier liquid comprising: a) liposome-forming structures comprising i. a therapeutically effective amount of cyclosporine A (CsA); ii. a membrane forming substance selected from the group of phospholipids; and iii. a solubility enhancing substance selected from the group of non-ionic surfactants; and b) at least one disaccharide selected from the group consisting of saccharose, lactose and trehalose, wherein the at least one disaccharide is present in an amount of at least 40 wt.-% with regard to the total weight of the lyophilized composition.

Abstract: A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises: a) at least one bilayer-forming lipid; b) a polymeric compound having the general formula I: wherein m, n, L, X, Y, and Z are as defined herein; and c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.

Abstract: Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.

Abstract: Methods of loading extracellular vesicles with payload molecules via homogenization are disclosed herein.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”).

Abstract: A method of forming an inhalable powder composition including combining sugar or a sugar alcohol with an active agent and a liquid carrier to form a liquid mixture, and freeze drying the liquid mixture to form crystalline dry composition, and then milling the crystalline dry composition to from crystalline dry powder particles having a particle size of about 5 micrometers or less.

Abstract: Provided are a hydroxyalkylalkyl cellulose excellent in formability and not causing marked delay in disintegration when added even in a small amount; a solid preparation including the hydroxyalkylalkyl cellulose; and a method for producing the solid preparation. More specifically, provided are a hydroxyalkylalkyl cellulose for tableting having a specific surface area of from 0.5 to 5.0 m2/g as measured by BET and a solid preparation including the hydroxyalkylalkyl cellulose.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising levodopa.

Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient, glyceryl palmitostearate, and D-?-tocopherol polyethylene glycol succinate (TPGS). Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of treatment are also described.

Abstract: The present disclosure is generally directed to methods for forming a polymeric particle according to an emulsification/solvent extraction methodology. The method includes combining an aqueous phase with an organic phase to form an emulsion that includes droplets of the organic phase dispersed in the aqueous phase. The aqueous phase may include a first emulsifier. The organic phase includes a second emulsifier and a biocompatible polymer dissolved in a solvent. The method includes removing at least a portion of the solvent from the organic phase upon which the biocompatible polymer solidifies to form a polymeric particle. The second emulsifier is present at a surface of the solidified polymeric particle.

Abstract: The present invention pertains to extracellular vesicles (EVs), wherein the EVs comprise domains present on the surface of the EV, which modify the circulation time of such EVs. Such EVs display improved pharmacokinetics and are therefore useful as therapeutics. Such EVs may also be useful for affinity purification of the EV drug substance.

Abstract: The present invention relates to a process for preparing an orally administered pharmaceutical composition with colonic delivery, comprising at least one core and a coating layer, making it possible to obtain a pharmaceutical composition which exhibits uniform and reproducible dissolution and therefore likewise uniform and reproducible release of the active ingredient with low coefficients of variation, said process being characterized in that it comprises the following steps: a) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 and at least one active ingredient intended to be delivered in the colon; or a?) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.

Abstract: The present invention relates to a nanohelix-substrate complex for controlling adhesion and polarization of macrophages, a manufacturing method thereof, and a method of controlling adhesion and polarization of macrophages by using the nanohelix-substrate complex, and the method of controlling adhesion and polarization of macrophages may temporally and reversibly control adhesion and phenotypic polarization of macrophages in vivo and ex vivo by controlling application/non-application of a magnetic field to the nanohelix-substrate complex.

Abstract: Methods of potentiating chemotherapy or radiotherapy are disclosed. The methods comprise administering to a subject in need of chemotherapeutic or radiotherapeutic treatment an effective amount of a composition comprising biocompatible nanoparticles under conditions in which the nanoparticles alter one or more cell regulatory mechanisms in cells in which the nanoparticles are localised or other cells. Then one or more doses of a chemotherapeutic or radiotherapeutic treatment are administered to the subject either concurrently with or after the nanoparticles have altered the one or more cell regulatory mechanisms in the cells in which the nanoparticles are localised or other cells. Also disclosed are methods of enhancing the effects of chemotherapy or radiotherapy on a cell population, methods of increasing the amount of strand breaks in DNA in a cell, and methods of inducing cancer cell death.